Health benefits attributed to 17α-estradiol, a lifespan-extending compound, are mediated through estrogen receptor α

Shivani N. Mann(University of Oklahoma Health Sciences Center), Niran Hadad(Jackson Laboratory), Molly Nelson Holte(Mayo Clinic), Alicia R Rothman(University of Oklahoma Health Sciences Center), Roshini Sathiaseelan(University of Oklahoma Health Sciences Center), Samim Ali Mondal(University of Oklahoma Health Sciences Center), Martin‐Paul Agbaga(Dean McGee Eye Institute), Archana Unnikrishnan(University of Oklahoma Health Sciences Center), Malayannan Subramaniam(Mayo Clinic), John R. Hawse(Mayo Clinic), Derek M. Huffman(Albert Einstein College of Medicine), Willard M. Freeman(Oklahoma Medical Research Foundation), Michael B. Stout(University of Oklahoma Health Sciences Center)
eLife
December 8, 2020
Cited by 52Open Access
Full Text

Abstract

Metabolic dysfunction underlies several chronic diseases, many of which are exacerbated by obesity. Dietary interventions can reverse metabolic declines and slow aging, although compliance issues remain paramount. 17α-estradiol treatment improves metabolic parameters and slows aging in male mice. The mechanisms by which 17α-estradiol elicits these benefits remain unresolved. Herein, we show that 17α-estradiol elicits similar genomic binding and transcriptional activation through estrogen receptor α (ERα) to that of 17β-estradiol. In addition, we show that the ablation of ERα completely attenuates the beneficial metabolic effects of 17α-E2 in male mice. Our findings suggest that 17α-E2 may act through the liver and hypothalamus to improve metabolic parameters in male mice. Lastly, we also determined that 17α-E2 improves metabolic parameters in male rats, thereby proving that the beneficial effects of 17α-E2 are not limited to mice. Collectively, these studies suggest ERα may be a drug target for mitigating chronic diseases in male mammals.


Related Papers

No related papers found

Powered by citation graph analysis